Loading...
XNASCSBR
Market cap135mUSD
Jan 17, Last price  
9.78USD
1D
-1.71%
1Q
121.27%
Jan 2017
286.56%
Name

Champions Oncology Inc

Chart & Performance

D1W1MN
XNAS:CSBR chart
P/E
—
P/S
2.69
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.79%
Rev. gr., 5y
13.13%
Revenues
50m
-6.90%
1,797,283001,399,9403,710,0004,893,0006,882,0007,149,0008,265,00011,550,0008,863,00011,182,00015,411,00020,241,00027,067,00032,123,00041,040,00049,109,00053,870,00050,155,000
Net income
-7m
L+36.38%
-246,544-303,718-170,05835,698-2,242,000-2,923,000-3,802,000-8,661,000-6,446,000-7,406,000-13,140,000-10,446,000-6,884,000-1,505,000128,000-1,975,000362,000548,000-5,335,000-7,276,000
CFO
-6m
L
-35,603-93,973-78,475792,404-888,000-2,100,000-54,000-5,227,000-4,262,000-3,433,000-9,630,000-6,452,000-2,840,000-1,226,0001,862,0002,905,000-1,681,0006,497,0003,955,000-6,137,000
Earnings
Mar 10, 2025

Profile

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
URL
https://championsoncology.com
IPO date
Nov 30, 1988
Employees
230
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑042016‑042015‑04
Income
Revenues
50,155
-6.90%
53,870
9.69%
49,109
19.66%
Cost of revenue
57,076
58,319
48,502
Unusual Expense (Income)
NOPBT
(6,921)
(4,449)
607
NOPBT Margin
1.24%
Operating Taxes
(32)
68
35
Tax Rate
5.77%
NOPAT
(6,889)
(4,517)
572
Net income
(7,276)
36.38%
(5,335)
-1,073.54%
548
51.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
(634)
(74)
207
BB yield
0.96%
0.11%
-0.19%
Debt
Debt current
2,674
2,416
1,054
Long-term debt
13,523
15,990
17,878
Deferred revenue
Other long-term liabilities
401
551
391
Net debt
13,579
8,288
9,925
Cash flow
Cash from operating activities
(6,137)
3,955
6,497
CAPEX
(836)
(2,872)
(2,384)
Cash from investing activities
(836)
(2,872)
(2,384)
Cash from financing activities
(527)
11
207
FCF
870
(3,657)
(181)
Balance
Cash
2,618
10,118
9,007
Long term investments
Excess cash
110
7,424
6,552
Stockholders' equity
(84,579)
(77,303)
(71,968)
Invested Capital
91,844
92,297
90,921
ROIC
0.63%
ROCE
3.20%
EV
Common stock shares outstanding
13,548
13,542
14,160
Price
4.85
-1.42%
4.92
-35.94%
7.68
-28.42%
Market cap
65,706
-1.38%
66,624
-38.73%
108,747
-30.46%
EV
79,285
74,912
118,672
EBITDA
(5,054)
(2,203)
2,234
EV/EBITDA
53.12
Interest
24
Interest/NOPBT
3.95%